A Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Daily Doses of ELND006 in Healthy Elderly Subjects.
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2011
At a glance
- Drugs ELND 006 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 02 Aug 2011 New trial record